<DOC>
	<DOCNO>NCT02989168</DOCNO>
	<brief_summary>This open label study eligible IPF subject use supplemental oxygen rest receive GBT440 orally daily .</brief_summary>
	<brief_title>Study Evaluate Effect GBT440 Administered Subjects With IPF Supplemental Oxygen Rest</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
	<mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
	<criteria>Documented diagnosis IPF . Receiving supplemental oxygen use rest . Weight â‰¥ 40 kg . Male female child bear potential willing able use highly effective method contraception study start 30 day last dose study drug . FEV1/FVC &lt; 70 % History interstitial lung disease . Subject plan begin commence pulmonary rehabilitation within 30 day screen . Corticosteroid ( &gt; 10 mg per day prednisone equivalent ) administer 7 day longer , within 30 day screen . Participated another clinical trial investigational drug ( medical device ) within 30 day 5halflives , whichever longer , prior screen , currently participate another trial investigational drug ( medical device ) . Female breastfeed pregnant Current smoker history smoking within 3 month screen</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Idiopathic pulmonary fibrosis</keyword>
	<keyword>hypoxemia</keyword>
	<keyword>oxygen</keyword>
</DOC>